Key Quantitative Figures & Financial Implications
The quantifiable monetary impact is limited to the amount finally levied by the Bengaluru North City Corporation (BNCC) or Greater Bengaluru Authority (GBA). The likely improvement charges should not exceed INR 70.8 million. In addition, there is likely to be applicable interest as computed by the BNCC / GBA. The company has presently made an additional provision of INR 156.1 million in its books of accounts based on its estimates.
Details of the Proceedings & Anticipated Action
The disclosure states that a revised demand notice is anticipated from the BNCC or GBA (successor to Bruhat Bengaluru Mahanagara Palike) for improvement charges and applicable interest. This follows the dismissal of a Writ Appeal filed before the Hon'ble High Court of Karnataka. The applicable laws are the Greater Bengaluru Governance Act, 2024 read with the Karnataka Municipal Corporations Act, 1976.
No compensation or penalty has been paid. The company states it will examine the demand and the underlying computation upon receipt and, based on the outcome, will take appropriate action.
Parties Involved
- Issuing Company: AstraZeneca Pharma India Limited
- Regulatory Authority (Counterparty): Bengaluru North City Corporation (BNCC) or Greater Bengaluru Authority (GBA)